Table 2.
Association between site of first metastatic disease recurrence and both CTC status at baseline (i.e. before chemotherapy) and CTC status after chemotherapy (n = 206: all patients with CTC assessment at baseline, i.e., before chemotherapy; n = 159: only patients with CTC assessment both before and after chemotherapy).
| Location of First Distant Recurrence | CTC Status at Baseline (n = 206) |
CTC Status at Baseline (n = 159) |
CTC Status after Chemotherapy (n = 159) |
|||
|---|---|---|---|---|---|---|
| CTC Negative (n = 136) |
CTC Positive (n = 70) |
CTC Negative (n = 107) |
CTC Positive (n = 52) |
CTC Negative (n = 115) |
CTC Positive (n = 44) |
|
| Bone only | 26 (19.1%) | 18 (25.7%) | 24 (22.4%) | 12 (23.1%) | 23 (20.0%) | 13 (29.5%) |
| Visceral only | 45 (33.1%) | 15 (21.4%) | 36 (33.6%) | 12 (23.1%) | 37 (32.2%) | 11 (25.0%) |
| Other site only | 51 (37.5%) | 23 (32.9%) | 37 (34.6%) | 15 (28.8%) | 41 (35.7%) | 11 (25.0%) |
| Multiple sites | 14 (10.3%) | 14 (20.0%) | 10 (9.3%) | 13 (25.0) | 14 (12.2%) | 9 (20.5%) |